A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Egypt

Hereditary angioedema (HAE) is a rare condition. It causes sudden swelling under the skin and inside the body, like in the belly, throat, or genitals. This swelling happens because of a temporary leak in blood vessels. HAE is classified based on the amount of a protein in the blood called C1 inhibitor (C1-INH): HAE with normal C1-INH levels and HAE with limited or insufficient C1-INH levels (C1-INH deficiency); HAE with C1-INH deficiency can be divided into Type1, with low levels of C1-INH, and Type 2, in which the protein is there, but does not work properly. This study will look at people with HAE Type1 or Type2. The main aim of this study is to describe the diagnosis and management of people with HAE Type1 or HAE Type2 in Egypt. Other aims are to learn more about people with HAE Type1 or Type2, including, but not limited to, other conditions they may have, family history, impact of HAE on daily life, if treatment is stopped and the reasons. During the study, information from already existing data in a participant's medical record will be reviewed and new data will be collected during routine visits of a participant to the study clinic.

Inclusion Criteria: Retrospective Phase: 1. The participant has a confirmed HAE-C1INH type1 or type2 diagnosis in medical records (based on clinical history and/or laboratory diagnosis in medical records). 2. The participant was diagnosed and/or treated from January 2015 to August 2025. Inclusion Criteria: Prospective Phase: 1. The participant has a physician-confirmed HAE-C1INH type1 or type2 diagnosis (based on clinical history and/or laboratory diagnosis). 2. The participant signed an informed consent or assent. 3. The participant should have had at least one visit to the treating physician/investigator during enrollment and the follow-up period. 4. The participant was not enrolled in the study's retrospective phase. Exclusion Criteria: (For both retrospective and prospective phases): 1. Participant with AAE-C1INH (acquired angioedema), drug-induced angioedema (AE-DI) (example angiotensin-converting enzyme inhibitors-I \[ACE-I\] angioedema), allergic mediated angioedema, inflammatory angioedema, or idiopathic angioedema. 2. HAE participants with normal C1-INH (HAE-nC1INH). 3. Participant deemed unsuitable for participation for any reason, based on the investigator's clinical judgment.